Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK

INTRODUCTION: Diabetes-related costs make up a large portion of healthcare expenditures in the UK. Many of these costs are related to treatment of diabetes-related complications. Reducing HbA1c to <7.0% (53 mmol/mol) reduces the incidence of complications and comorbidities. Metformin plus sulfony...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Achha, Sayeed, Neslusan, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630566/
https://www.ncbi.nlm.nih.gov/pubmed/28948541
http://dx.doi.org/10.1007/s13300-017-0312-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630566/
https://www.ncbi.nlm.nih.gov/pubmed/28948541
http://dx.doi.org/10.1007/s13300-017-0312-1

Ejemplares similares